Skip to main content
Midas Edge

RIGEL PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed May 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

RIGEL PHARMACEUTICALS, IN****C.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025

INDEX

​ · ​ · ​
​​​Page
PART IFINANCIAL INFORMATION​3
Item 1.Financial Statements​3
​Condensed Balance Sheets — March 31, 2025 (Unaudited) and December 31, 2024​3
​Condensed Statements of Operations (Unaudited) — three months ended March 31, 2025 and 2024​4
​Condensed Statements of Comprehensive Income (Loss) (Unaudited) — three months ended March 31, 2025 and 2024​5
​Condensed Statements of Stockholders’ Equity (Deficit) (Unaudited) — three months ended March 31, 2025 and 2024​6
​Condensed Statements of Cash Flows (Unaudited) — three months ended March 31, 2025 and 2024​7
​Notes to Condensed Financial Statements (Unaudited)​8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations​26
Item 3.Quantitative and Qualitative Disclosures About Market Risk​46
Item 4.Controls and Procedures​47
PART IIOTHER INFORMATION​47
Item 1.Legal Proceedings​47
Item 1A.Risk Factors​48
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds​100
Item 3.Defaults Upon Senior Securities​100
Item 4.Mine Safety Disclosures​100
Item 5.Other Information​100
Item 6.Exhibits​101
​​​​
Signatures​102
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.